LOGIN
THR: Single pamidronate dose doesn't prevent development of osteolytic lesions
August 2013
THR: Single pamidronate dose doesn't prevent development of osteolytic lesions
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
Clinical and radiological outcome of total hip replacement five years after pamidronate therapy
J Bone Joint Surg Br. 2006 Oct;88(10):1309-15.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
50 patients that underwent total hip replacements in 56 hips and were randomized to receive either a single intravenous infusion of pamidronate or a placebo to determine their effects of peri-prosthetic bone mineral density. After 5 years 37 patients (42 hips) returned for assessment. Throughout the course of the study the pamidronate group and placebo group achieved similar Harris hip scores and ...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.